Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 15 chart positions in 15 markets.
By chart position
- 🇺🇸US · Medicine#6830K to 100K
- 🇦🇺AU · Medicine#2005K to 30K
- 🇸🇪SE · Medicine#7710K to 30K
- 🇳🇱NL · Medicine#9310K to 30K
- 🇩🇰DK · Medicine#4910K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
24K to 83K🎙 Daily cadence·183 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
80K to 278K🇺🇸36%🇦🇺11%🇸🇪11%+12 more - Active Followers
Loyal subscribers who consistently listen
32K to 111K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
How To Get $50 GLP-1
Jun 23, 2026
Unknown duration
What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs
Jun 16, 2026
Unknown duration
Retatrutide Just Reached Bariatric Surgery Results
Jun 11, 2026
Unknown duration
Retatrutide Before FDA Approval? Lilly Just Changed the Conversation
Jun 9, 2026
Unknown duration
Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs
Jun 2, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 6/23/26 |  How To Get $50 GLP-1 | Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode of On The Pen, Dave Knapp sits down with obesity medicine expert Angela Fitch to break down exactly who qualifies, how to apply, which medications are covered, and what this historic expansion of obesity treatment access means for patients across America.We discuss:✅ Medicare Bridge Program eligibility requirements✅ Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates✅ BMI and comorbidity qualifications✅ Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access✅ How Medicare patients can obtain GLP-1 medications✅ Why obesity is finally being treated as a chronic disease✅ The future of obesity medicine and Medicare coverage✅ Concerns about access to care vs access to medication✅ Muscle loss, nutrition, strength training, and healthy weight loss✅ The Treat and Reduce Obesity Act (TROA)This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care.📖 Read more obesity medicine news at Obesity.News🔗 All links: linktr.ee/manonthemounjaro#GLP1 #Medicare #Zepbound #Wegovy #Obesity #WeightLoss #ObesityMedicine #MedicareBridgeProgram #Tirzepatide #Semaglutide #Foundayo #Orforglipron #Prediabetes #Type2Diabetes #WeightManagement #AngelaFitch #OnThePen #MedicareCoverage #GLP1News #ObesityTreatment #HealthcarePolicy #WeightLossMedication #ChronicDisease #Mounjaro #Retatrutide #Lilly #NovoNordisk #ObesityAdvocacy #GLP1Community #MedicarePatients | — | ||||||
| 6/16/26 | What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs | ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?In this episode:✅ Survodutide obesity and liver fat reduction data✅ Mazdutide Phase 3 obesity and diabetes results✅ UBT251 triple agonist weight loss data✅ Berobenatide (MET-097) long-acting GLP-1 updates✅ CagriSema diabetes and obesity trial results✅ Zenagamtide (Amycretin) injectable and oral development✅ Petrelintide amylin agonist info✅ Future GLP-1, GIP, glucagon, and amylin therapiesThe future of obesity medicine is no longer just about who produces the most weight loss. It’s about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.Read more obesity medicine news at obesity.news🔗 Linktree: linktr.ee/manonthemounjaro#ADA2026 #Retatrutide #CagriSema #Survodutide #Mazdutide #UBT251 #Berobenatide #MET097 #Zenagamtide #Amycretin #Petrelintide #Inisepatide #Elcaglipron #GLP1 #ObesityMedicine #WeightLoss #Type2Diabetes #Zepbound #Mounjaro #Wegovy #GLP1News #ObesityResearch #DiabetesResearch #OnThePen | — | ||||||
| 6/11/26 |  Retatrutide Just Reached Bariatric Surgery Results | Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide's potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.otplinks.com | — | ||||||
| 6/9/26 |  Retatrutide Before FDA Approval? Lilly Just Changed the Conversation | Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide. | — | ||||||
| 6/2/26 |  Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs | Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who suggested that obesity could become a solved disease within just a few generations of innovation.What does that mean for the millions of patients still fighting for access to GLP-1 medications like Zepbound, Mounjaro, and tirzepatide? And what is Lilly seeing in its pipeline that the rest of us can't?We dig into:Lilly's decision to stop disclosing its Phase 1 pipelineThe Camurus fluid crystal technology deal and what it means for long-acting GLP-1sEloralintide — Lilly's selective amylin agonist and potential dark horse in obesity medicineHow eloralintide compares to Novo Nordisk's cagrilintideWhy the future of obesity treatment is a toolbox, not a scoreboardThe access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gapsRetatrutide, quintuple agonists, and what's coming out of ADA 2026If you're on Zepbound, Wegovy, Ozempic, or any GLP-1 medication — or you're waiting for the next generation of obesity drugs — this episode is for you.🔔 Subscribe for weekly updates on obesity medicine, GLP-1 news, and what it all means for patients.💊 Sponsored by Shed — visit TryShed.com and use code OTP25 to save 25% on obesity care. | — | ||||||
| 5/26/26 |  Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War | https://linktr.ee/manonthemounjaro | — | ||||||
| 5/19/26 |  Lilly Bets $8B on Weight Loss Future | https://linktr.ee/manonthemounjaro | — | ||||||
| 5/12/26 | The Next Two Weeks in GLP1 Are Huge, Here's Why | http://www.otplinks.com | — | ||||||
| 5/5/26 |  He Took Retatrutide 40mg and Proved a Point | This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safety and patient safety, especially concerning prescription drugs.The discussion also touches upon a recent report of liver failure following the Foundayo launch, emphasizing the need for vigilant drug safety and thorough error analysis to prevent future incidents.https://www.otplinks.com1. 🚨 The 40mg Retatrutide Overdose Case — 0:00:02A 32-year-old self-administered gray market Retatrutide, forgot he'd dosed, injected again — hitting 40mg. The setup for the whole episode.2. 🏥 What Actually Happened to Him (ER Visit & Why It Matters) — 0:05:02Deep dive into the published medical case: severe diarrhea, dehydration, kidney danger, and the frightening ease with which it happened.3. ⚠️ Gray Market GLP-1s: The Real Risk Nobody's Talking About — 0:07:20How buying unregulated research peptides means guessing on purity, dose, and contents — and why that's terrifying at scale.4. 💊 Orforglipron (Fondayo) & the Liver Failure Report — 0:13:00 (approx.)One month after Fonda's launch, a liver failure report emerges. The FDA's concerns, elevated liver enzymes in trials, and why Lilly scaled back from 45mg to 36mg in Phase 3.5. 🔗 How These Two Stories Connect: Clinical Trials vs. the Real World — 0:16:31The through-line of the episode: drugs behave differently outside controlled settings. Peptide influencers hawking research-grade OrforglprIon pills mid-fast is the canary in the coal mine.6. 🚪 Compounding Access Is Being Squeezed — State Boards, Lawsuits & the Gray Market Funnel — 0:19:06State medical boards in CA, RI, and KY pressuring doctors. As regulated access tightens, patients don't stop — they just shift to riskier sources.7. 📱 Introducing the Pivot App: A GLP-1 Tracking Tool for Patients — 0:21:55Interview with Shed's Chief Product Officer Kyler Ockey about the Pivot app — dose logging, daily habit tracking, weekly check-ins, and why patient self-tracking is critical to safe GLP-1 use. | — | ||||||
| 4/30/26 |  Eli Lilly Earnings Call Recap: Q1 2026 | We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of the numbers that were so incredible to hear. This video analyzes Eli Lilly's Q1 2026 earnings call, discussing key products like eloralintide, brenipatide, and retatrutide, providing essential finance news and stock market news for those tracking pharmaceutical companies. The presenter highlights the strong start of Foundayo's U.S. launch and reviews the Lilly Select Pipeline, touching upon the U.S. Incretin Analogs Market and broader healthcare industry trends.WAYS TO SUPPORT MY WORK ⬇️http://www.otplinks.com💊 OVER THE COUNTER ORAL PEPTIDE SUPPLIMENTS: BPC-157 // Can’t Weight // TB4-FRAG // KPVSign up here and use code “OTP10” to save 10%https://integrativepeptides.com/OTPWHY I TRUST INTEGRATIVE PEPTIDES:🇺🇸 Made in the USA📋 CGMP Compliant (FDA oversight of their products)🧑⚕️Trusted and Sold By Doctors and Clinics all over the USA📕 GET MY BOOK! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapphttps://amzn.to/4gAXrz4 | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/28/26 |  SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story | https://www.otplinks.comA new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid. But that is not the real story. Even when people successfully lose weight, a large percentage gain it back, and for years that has been framed as a failure of discipline or willpower.This episode breaks down new research that helps explain why that happens. A study published in EMBO Reports shows that obesity can leave lasting changes at the cellular level through epigenetics, where gene activity is altered without changing the DNA itself. Researchers found that immune cells remained in a pro inflammatory, metabolically altered state even after weight loss, with some of these changes potentially lasting for years.In practical terms, this means the body does not simply return to a neutral baseline after weight loss. It can continue to operate as if it is still in an obese state, which helps explain why so many people feel like their body is working against them. This shifts the conversation away from personal responsibility and toward biology, reinforcing the idea that obesity is a chronic, relapsing metabolic disease.That distinction matters because it changes how treatment should be approached. If the underlying biology does not fully reset, then short term solutions are unlikely to be effective long term. These medications may not just be tools for losing weight, but part of ongoing management for a system that retains a memory of obesity and requires continued intervention. | — | ||||||
| 4/23/26 |  BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out! | Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what’s driving the FDA’s increased enforcement and why these shutdowns could signal a broader shift in the compounded medication market.Joined by Sabina Hemmi from glpwinner.com, we break down the key differences between 503A and 503B pharmacies, what these changes mean for supply and patient access, and why delays in prescriptions may be on the horizon. We also dive into the growing legal battles between pharma companies and telehealth providers and what that could mean for the future of affordable GLP-1 options.If you’re using or considering compounded GLP-1s, this episode covers what you need to know right now and what could be coming next. | — | ||||||
| 4/21/26 |  Retatrutide Could Change Everything… But Who Actually Gets It? | ON THE PEN RESOURCES AND LINKS: HTTPS://WWW.OTPLINKS.COMWhat if the most powerful obesity drug ever created ends up being the one you can’t get?That’s the real conversation around retatrutide right now.In this video, I break down what Eli Lilly is doing behind the scenes, and why this isn’t just about whether retatrutide is better than tirzepatide. This is about strategy. This is about access. And this is about who gets left behind.We’re talking about:• The push to classify retatrutide as a biologic• Why that could mean pricing in the $7,000/month range• How LillyDirect is changing access to tirzepatide• The “two lane” system that could define obesity treatment going forward• And what this means for patients already struggling to stay on GLP-1 therapiesIf you’ve ever fought insurance, dealt with compounding disappearing, or felt like the system decides what you’re allowed to have… this one is for you.👇 Let’s talk about itHave you ever felt stuck between “this is working” and “this isn’t enough”… with no clear path forward? | — | ||||||
| 4/19/26 |  Ozempic Personality With Dr Spencer Nadolsky | This conversation dives headfirst into one of the most controversial and least understood side effects of GLP-1 medications, what many are now calling the “Ozempic personality.” In this candid interview, Dr. Spencer Nadolsky joins On The Pen to unpack the growing reports of anhedonia, a flattening of motivation, desire, and emotional highs that some patients experience, especially at higher doses of tirzepatide and similar therapies.What starts as a discussion about how these medications work in the brain quickly turns into something much deeper. We explore how GLP-1 and GIP receptor agonists don’t just reduce hunger, they fundamentally alter the brain’s reward system, dampening cravings, food noise, and in some cases, the very drive to seek pleasure at all. That is where the idea of the “Ozempic personality” begins to take shape, not as a diagnosis, but as a shared patient experience that is only now being taken seriously.Dave opens up about his own journey, spending years at the highest dose and slowly realizing that while the medication gave him control over food and blood sugar, it also quietly muted parts of his identity. Hobbies faded. Motivation shifted. The highs and lows of life became more… flat. And it wasn’t until stepping away that he could see the contrast clearly.Dr. Nadolsky brings clinical perspective to match the lived experience, explaining how this isn’t classic depression, but something more nuanced. Patients aren’t necessarily sad, they just stop wanting things. He shares how often this shows up in his practice, how he identifies it, and most importantly, how adjusting dose rather than stopping treatment altogether can restore balance.The conversation also raises bigger questions about transparency in clinical trials, what drug companies knew about these “anti-hedonic” effects, and why something so impactful may not have been formally tracked. At the same time, both Dave and Dr. Nadolsky emphasize what matters most, these medications are still life changing, even life saving, but they are not one size fits all.If you’ve ever felt like something changed beyond just your appetite while on a GLP-1, this is the conversation you’ve been waiting for. It puts language to an experience thousands are having but struggling to explain, and it gives you something even more important, a path forward.Watch the full interview to understand the reality behind the “Ozempic personality,” how to recognize it, and how to work with your doctor to find your own sweet spot. | — | ||||||
| 4/14/26 |  Foundayo GLP-1 Pill: FDA Needs More Data | Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use. Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety. | — | ||||||
| 4/7/26 |  GLP-1 Access Is EXPLODING… But Something Else Is Happening | If you just look at the headlines, things look great for access to GLP-1 medications but for some of those already using these medications things are changing and getting tighter. Listen in as Dave breaks down the news of the week and puts it all in context.Topics:The GLP-1 paradox, Rise of telehealth powerhouses, FDA guidance on compounding, Enforcement risks and industry impact, Peptide imports and gray market concerns, New branded drug developments, Expansion of oral GLP-1 medications, New oral drug launches, Where the market is heading. | — | ||||||
| 4/2/26 |  Zepbound Dosing: What Your Doctor Didn't Explain | Are you on tirzepatide or semaglutide and struggled with inconsistent weight loss and side effects? On this episode of On The Pen, Dave Knapp and Dr. Ian Ellis dive into the surprising variability of GLP-1 dosing (retatrutide, tirzepatide), even when the weekly dose remains the same. We explore how these subtle dosage changes can lead to frustrating glp-1 side effects and why many individuals eventually give up on their weight loss medication. This new way of thinking about glp-1 dosing could change the obesity medicine game. Referenced Links: http://www.OTPLinks.com00:00 Why most GLP-1 users are never on the same dose twice01:55 Dr. Ian's background: trainer, nutritionist, ER physician04:00 His obsessive relationship with food and body composition07:45 The two impossible choices: obsession or obesity10:12 How medical school destroyed his health10:25 A colleague mentions Ozempic for the first time11:35 His first dose and what real satiety feels like13:00 Why the same dose felt worse every single week15:00 30 lbs lost but the body scan results were horrifying17:30 Why elderly patients are especially at risk on GLP-1s18:35 Patient case: Pat May, 310 lbs, lost over 100 lbs20:45 Semaglutide half-life and dose stacking explained24:50 The therapeutic window and finding your ideal level26:30 Why the dosing protocol was built for trials not people28:00 You are never on the same drug level twice29:00 Patient case: Mary Alice lost 30 lbs below the starting dose32:00 The math behind calculating your precise GLP-1 level35:00 The VoaFit app and making precision dosing scalable36:00 Their patients lost more weight using half the medicine39:30 Why 40 to 70 percent of people quit GLP-1s42:00 Compounding pharmacies and the case for flexible dosing46:00 Using GLP-1 as a thermostat dial for your appetite56:45 Where precision dosing is available now58:30 Beyond GLP-1s: applying this to testosterone and more1:05:30 Why hitting the dose ceiling kills long-term results1:07:00 Dr. Ian's outcome: off GLP-1s completely1:10:00 Fixing a broken one-size-fits-all dosing paradigm1:13:00 How to find Dr. Ian Ellis and VoaFit | — | ||||||
| 3/31/26 |  Wegovy Price Drop Exposes a Bigger Problem | A major shift in obesity treatment is underway following a surprising pricing move that could change how patients access care. This episode explores the growing divide between traditional healthcare and alternative pathways, the real tradeoffs behind cost and safety, and what the future may hold for medications, access, and long term health.TOPICS:Wegovy Price Drop Changes EverythingWhat This Podcast CoversNew Savings Programs ExplainedWhy This Is Bigger Than PriceThe Broken Healthcare SystemRise of Telehealth & CompoundingThe New Parallel System of CareGray Market vs Medical AccessSafety vs Strength DebateRisks of Unregulated MedicationsWhy Long-Term Support MattersGray Market Supply ConcernsPharma Pressure & RegulationWhat Happens If Access ChangesTrust Issues with the System The Core Question: Safety or PowerAre OTC GLP-1s Coming?New Oral Drugs & NexboundWhy Pills Could Change EverythingAccess vs CareGLP-1s as Longevity DrugsEli Lilly’s Big Bet on the FutureThe Next 5–10 Years | — | ||||||
| 3/24/26 |  Retatrutide Is Too Good… And That’s The Problem | Access to compounded and research-grade GLP-1s may be tightening, as comments from Robert F. Kennedy Jr. signal increased enforcement and a push back toward branded medications. At the same time, new data on retatrutide shows powerful results for people with type 2 diabetes, while drug companies are already developing next-generation therapies beyond GLP-1s. Todat's topics:The Throttling of Compounded GLP-1sFDA vs Telehealth, What’s Really HappeningThe Truth About “Research Peptides”The Rule That Created the Black Market If You Rely on This, Here’s What’s ComingWhy They Want You Back on Branded DrugsRetatrutide Might Be the Most Powerful YetThe Data That Changes Everything (Diabetes + Weight Loss)What Comes After GLP-1s, The Next Wave | — | ||||||
| 3/17/26 |  MASSIVE: Compound Tirzepatide and Semaglutide Updates! | On The Pen breaks down the latest GLP-1 news, compounded semaglutide updates, tirzepatide controversy, FDA and DDC list developments, Novo Nordisk findings, Eli Lilly B12 tirzepatide concerns, and new oral obesity drug data from Structure Therapeutics. If you follow obesity medicine, weight loss drugs, peptide news, semaglutide, Zepbound, Wegovy, Ozempic, Mounjaro, and patient advocacy, this episode is for you.WAYS TO SUPPORT MY WORK ⬇️http://www.otplinks.com00:00 Massive compound shakeup00:00:43 Why compound users need this00:01:25 Sponsor, Shed obesity care00:02:11 Breaking news changed everything00:02:28 OTP semaglutide exclusive00:03:28 DDC list explained00:04:24 Novo’s lab findings00:09:57 302% dose shocker00:13:03 Catalent’s contamination mess00:16:33 Lilly’s B12 tirzepatide bombshell00:19:34 Is the molecule changing?00:21:46 New oral GLP-1 contender | — | ||||||
| 3/10/26 |  Cheap Zepbound Incoming for Medicare, But CMS Just Issued a Catch | Send a textOn this episode of the podcast, host Dave Knapp breaks down the latest updates on potential GLP-1 receptor agonists coverage for people on Medicare living with obesity. With new guidance released by the Centers for Medicare & Medicaid Services, the episode explains how two upcoming federal programs—the Bridge Program (2026) and the Balance Model (2027)—could expand access to medications like Zepbound and Wegovy.Listeners will learn who may qualify, how the proposed $50 monthly cost could work during the temporary Bridge Program, and why coverage could change once insurance plans become involved in 2027. The episode also outlines the role of the proposed Treat and Reduce Obesity Act and why long-term Medicare coverage still depends on congressional action.If you or a loved one are on Medicare and curious about access to GLP-1 medications for obesity treatment, this episode explains the key timelines, eligibility criteria, and practical steps patients should take with their doctors.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!🤝 Visit Our Sponsors!OTPLinks.com Decoding GLP-1 BookDecoding GLP-1: A Guide for Friends and Family of Those On The PenBuy Here: https://amzn.to/3Dc66d4MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join👉 My Amazon Affiliate Store:https://www.amazon.com/shop/manonthemounjaroonthepenWATCH MORE!📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.comThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com. | — | ||||||
| 3/3/26 |  Gray Market GLP-1 Is Booming Branded Access is Broken | Send a textEpisode Summary (Short Version):This week on On The Pen, Dave breaks down the rapid changes reshaping GLP-1 access — from new federal reforms targeting PBMs and possible FDA limits on compounded semaglutide, to Walgreens and Amazon launching cash-pay weight loss clinics.As insurance denials continue and out-of-pocket costs rise, patients are stuck between a shifting policy landscape and a growing direct-to-consumer market. Plus, an AI-designed oral GLP-1 enters Phase 3 trials, signaling how fast obesity medicine is evolving.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!🤝 Visit Our Sponsors!OTPLinks.com Decoding GLP-1 BookDecoding GLP-1: A Guide for Friends and Family of Those On The PenBuy Here: https://amzn.to/3Dc66d4MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join👉 My Amazon Affiliate Store:https://www.amazon.com/shop/manonthemounjaroonthepenWATCH MORE!📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.comThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com. | — | ||||||
| 2/24/26 |  UBT251 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE? | Send a textThis episode unpacks Novo’s aggressive price cuts, Lilly’s head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war.00:00 – Cold Open: Lilly vs Novo Shock TimingDave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match.03:20 – Novo Nordisk Price Cuts ExplainedDeep dive into Novo’s plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning.07:25 – Tirzepatide vs Semaglutide Head to Head TrialBreakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially.11:55 – Market Reaction and Strategic ImplicationsDiscussion of stock movement, competitive signaling, and how Novo’s pricing move may blunt Lilly’s trial victory.14:25 – Novo Triple Agonist Data DropsShift into Novo’s early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists.16:00 – Comparing Novo’s Triple to RetatrutideAnalysis of weight loss percentages versus Lilly’s retatrutide data and the caution required when comparing across trials.18:15 – The Triple Agonist EraBroader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term.20:00 – Clinical Trial Results vs Real World RealityReminder that clinical trial outcomes do not automatically translate to everyday patient experience.22:30 – Data Refresher on Allurion Ballon ApprovalQuick recap of the headline numbers and strategic landscape as innovation and pricing Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!🤝 Visit Our Sponsors!OTPLinks.com Decoding GLP-1 BookDecoding GLP-1: A Guide for Friends and Family of Those On The PenBuy Here: https://amzn.to/3Dc66d4MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join👉 My Amazon Affiliate Store:https://www.amazon.com/shop/manonthemounjaroonthepenWATCH MORE!📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.comThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com. | — | ||||||
| 2/17/26 |  Wegovy vs Zepbound in 2026: New Higher Dose | Send a textWegovy’s new 7.2 mg dose—three times higher than the current max—has just been approved in the EU, with U.S. approval expected soon. But now that Wegovy matches Zepbound on weight loss, the real question isn’t which drug helps you lose more weight—it’s which one treats your underlying metabolic disease more effectively.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!🤝 Visit Our Sponsors!OTPLinks.com Decoding GLP-1 BookDecoding GLP-1: A Guide for Friends and Family of Those On The PenBuy Here: https://amzn.to/3Dc66d4MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join👉 My Amazon Affiliate Store:https://www.amazon.com/shop/manonthemounjaroonthepenWATCH MORE!📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.comThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com. | — | ||||||
| 2/10/26 |  Compound Tirzepatide: Time to Stock Up? | Send a textThis week on The Weekly Dose, Dave Knapp breaks down the biggest questions shaking up the GLP-1 world. From whether patients should be stocking up on compounded injectables, to what Eli Lilly’s earnings call revealed about Zepbound QuickPens, refill rules, and the long-awaited retatrutide timeline, this episode covers it all. Dave also unpacks FDA enforcement signals, the escalating tension between Big Pharma and compounders, the Hims & Hers controversy, and what recent lawsuits and Super Bowl ads tell us about where obesity treatment is headed next. Clear context, real-world implications, and what patients should be discussing with their doctors right now.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!🤝 Visit Our Sponsors!OTPLinks.com Decoding GLP-1 BookDecoding GLP-1: A Guide for Friends and Family of Those On The PenBuy Here: https://amzn.to/3Dc66d4MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join👉 My Amazon Affiliate Store:https://www.amazon.com/shop/manonthemounjaroonthepenWATCH MORE!📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.comThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com. | — | ||||||
Showing 25 of 197
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
15 placements across 15 markets.
Chart Positions
15 placements across 15 markets.